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BACKGROUND & AIMS: There is an increasing need for new
treatments for patients with Crohn’s disease (CD) in whom pre-
vious therapy with tumor necrosis factor (TNF) antagonists has
failed. We performed a placebo-controlled, phase 3, double-blind
trial to evaluate the efﬁcacy and safety of vedolizumab, an anti-
body against the integrin a4b7, as induction therapy. METHODS:
Patients with moderately to severely active CD (CD activity index
[CDAI] score, 220–400 points) were assigned randomly to groups
given vedolizumab (300 mg) or placebo intravenously at weeks
0, 2, and 6. The primary analysis involved 315 patients with
previous TNF antagonist failure (ie, an inadequate response to,
loss of response to, or intolerance of 1 TNF antagonists); we
determined the proportion of patients in clinical remission (CDAI,
150 points) at week 6. Secondary analyses evaluated outcomes
at weeks 6 and 10 in this population and in the overall population
(N ¼ 416), which included patients naive to TNF antagonist
therapy (n ¼ 101). RESULTS: Among patients who had experi-
enced previous TNF antagonist failure, 15.2% of those given
vedolizumab and 12.1% of those given placebo were in remission
at week 6 (P ¼ .433). At week 10, a higher proportion of this
population given vedolizumab was in remission (26.6%) than
those given placebo (12.1%) (nominal P ¼ .001; relative risk, 2.2;
95% conﬁdence interval, 1.3–3.6). A higher proportion of patients
with previous TNF antagonist failure given vedolizumab also had
a CDAI-100 response (100-point decrease in CDAI score from
baseline) at week 6 than those given placebo (39.2% vs 22.3%;
nominal P ¼ .001; relative risk, 1.8; 95% conﬁdence interval,
1.2–2.5). Adverse event results were similar among all groups.
CONCLUSIONS: Vedolizumab was not more effective than pla-
cebo in inducing clinical remission at week 6 among patients with
CD in whom previous treatment with TNF antagonists had failed.
The therapeutic beneﬁts of vedolizumab in these patients were
detectable at week 10. ClinicalTrials.gov number: NCT01224171.Keywords: Anti–a4b7 Integrin; Anti-TNF Therapy; Randomized
Controlled Trial; Lymphocyte Trafﬁcking.
Watch this article’s video abstract and others at http://tiny.cc/j026c.Scan the quick response (QR) code to the left
with your mobile device to watch this article’s
video abstract and others. Don’t have a QR code
reader? Get one by searching ‘QR Scanner’ in
your mobile device’s app store.urrent therapies for Crohn’s disease (CD), a chronic
1Cinﬂammatory disorder of the alimentary tract, in-
clude corticosteroids; immunosuppressives (eg, azathioprine,
6-mercaptopurine, methotrexate); the tumor necrosis factor
(TNF) antagonists inﬂiximab, adalimumab, and certolizumab;
and the anti–a4 integrinmonoclonal antibodynatalizumab.
1–6
Treatment with TNF antagonists substantially has improved
the care of patients with CD that is refractory to other treat-
ments by inducing andmaintaining remission and decreasing
the need for hospitalization and surgery.7,8 However, in
controlled trials, approximately two thirds of patients did not
attain or maintain remission at 1 year after TNF antagonist
initiation.9–11 In addition, patients in whom 1 TNF antagonist
has failed have a substantially decreased response rate when
treated with a second TNF antagonist.12,13 Important safety
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of TNF antagonists, including an increased risk of serious
infections (eg, tuberculosis).14–16
Natalizumab, another option for patients with CD, binds to
a4b1 and a4b7 integrins, inhibiting T-lymphocyte adhesion to
vascular cell adhesion molecule-1 and mucosal addressin cell
adhesion molecule-1 (MAdCAM-1). Natalizumab is approved
for multiple sclerosis in many countries and for moderate to
severe CD in the United States.3,5,6 However, an increased risk
of progressive multifocal leukoencephalopathy (PML), a rare,
serious infection of the central nervous system (CNS), has
limited natalizumab use in patients with CD.17,18 Because of
these limitations with TNF antagonists and natalizumab,
therapies for patients with TNF antagonist failure are needed,
and those that selectively inhibit lymphocyte trafﬁcking to the
gut may yield important safety beneﬁts.
Vedolizumab is a humanized, anti–a4b7 integrin, immu-
noglobulin G1 monoclonal antibody.19 Unlike natalizumab,
vedolizumab speciﬁcally binds to the a4b7 integrin and
neither binds to nor inhibits the function of a4b1 or aEb7
integrins.19 The drug inhibits adhesion of a discrete gut-
homing subset of T lymphocytes to MAdCAM-1, but not to
vascular cell adhesion molecule-1.19 Selective inhibition of
the a4b7/MAdCAM-1 pathway should ameliorate gastroin-
testinal inﬂammation without inhibiting systemic immune
responses or affecting T-cell trafﬁcking to the CNS.20–23
The efﬁcacy, safety, and tolerability of vedolizumab in-
duction and maintenance therapies were established in the
pivotal GEMINI 2 study24 of patients with moderately to
severely active CD in whom 1 or more prior CD therapies had
failed. A second study (GEMINI 3) to assess efﬁcacy, safety,
and tolerability of vedolizumab induction therapy in patients
with moderately to severely active CD, which focused on pa-
tients with previous TNF antagonist failure, is reported here.
Materials and Methods
Objectives
The primary objective of this study was to determine the
effect of vedolizumab induction therapy on clinical remission
(Crohn’s Disease Activity Index [CDAI] score, 150 points) atFigure 1. Study design. aAfter the week 10 assessments, patien
well tolerated and no CD surgical intervention was required. bElig
the ﬁnal study drug dose. cPatients who were ineligible for or d
safety visit (week 22 or 16 weeks after the last dose) and compweek 6 in patients with CD and previous TNF antagonist failure
(ie,w75% of enrolled patients). Secondary objectives included
determining the effects of vedolizumab on the CDAI-100
response (CDAI score decrease of 100 points from baseline)
at week 6 and clinical remission at week 10 in the TNF
antagonist–failure population and on remission at weeks 6 and
10 in the overall population.
Study Design
This phase 3, randomized, placebo-controlled, double-blind,
multinational, multicenter trial was initiated in November 2010
and completed in April 2012 (GEMINI 3; ClinicalTrials.gov
NCT01224171; EudraCT 2009-016488-12). Institutional re-
view boards and/or independent ethics committees at each
investigational center approved the protocol (available at www.
gastrojournal.org; protocol C13011), which was not amended.
All patients provided written informed consent. All authors had
access to the data and reviewed and approved the ﬁnal
manuscript before submission.
A 21-day screening period was followed by a 10-week
treatment period (Figure 1). During screening, physical and
neurologic examinations were performed and medical history
(eg, prior and concomitant CD medications) and demographic
information were obtained. Blood tests, urinalysis, and stool
sample analysis for enteric pathogens and fecal calprotectin25
also were performed. Disease activity for eligibility was
assessed with the CDAI,26 an 8-component scale (range, 0 to
approximately 600; with higher scores indicating greater dis-
ease activity). Eligible patients then randomly were assigned
(1:1) to receive vedolizumab 300 mg or placebo, administered
intravenously in 250 mL of 0.9% sodium chloride at weeks 0, 2,
and 6. After the 10-week treatment phase, patients who had no
unacceptable adverse events (AEs) or did not require CD-
related surgery during the study were eligible for the long-
term, open-label extension (NCT00790933).
Randomization and Blinding
Investigators performed patient enrollment, monitored by
an interactive voice response system. Stratiﬁed block random-
ization was computer-generated centrally using 8 strata and a
block size of 16. Patients were stratiﬁed by previous TNFts were eligible to enroll in study C13008 if the study drug was
ible patients could enroll in study C13008 within 5 weeks after
eclined entry into study C13008 returned for a ﬁnal on-study
leted the 2-year follow-up evaluation.
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corticosteroid use (yes/no), and concomitant immunosup-
pressive use (yes/no).
Randomization schedules were generated by Takeda
Pharmaceuticals International Co (Cambridge, MA), and each
treatment-qualiﬁed patient received a unique randomization
number used to provide treatment assignments for dose
preparation via the interactive voice response system. Saline
bag covers and labels maintained blinding. Only the study site
pharmacist was aware of treatment assignments.Patients
Patients (at 107 sites in North America, Europe, Asia, Africa,
and Australia) were between 18 and 80 years of age and had a
diagnosis of CD with known involvement of the ileum and/or
colon at 3 ormoremonths before enrollment (Table 1). Diagnosis
was based on clinical and endoscopic evidence, corroborated by
results of histopathology (diagnosis occurred at 6 months
before enrollment if a histopathology report was unavailable).
All patients had CD that was moderately to severely active, as
determined by a CDAI score of 220–400 points within 7 days
before enrollment, and one of the following: a screening
C-reactive protein (CRP) level greater than 2.87 mg/L,25 a colo-
noscopy within the previous 4 months that documented ulcer-
ations, or a fecal calprotectin level greater than 250 mg/g stool
during screening in conjunction with features of active CD
supported by small-bowel imaging. All patients had experienced
an inadequate response, loss of response, or intolerance to TNF
antagonists, immunosuppressives, or corticosteroids within the
past 5 years (Supplementary Table 1).
Exclusion criteria included previous vedolizumab, natalizu-
mab, efalizumab, or rituximab exposure, as well as concurrent
lactation or pregnancy, unstable or uncontrolled medical condi-
tion, major neurologic disorder, general anesthesia within 30 days,
or planned major surgery during the study. Previous malignancies
with the exception of certain cancers for which the recurrence risk
after adequate treatment is expected to be low (eg, nonmetastatic
basal cell and squamous cell skin cancers, cervical carcinoma in
situ) resulted in exclusion, as did active drug or alcohol depen-
dence and active psychiatric disease or other complicating fac-
tor(s) that could result in nonadherence to study procedures.Efﬁcacy Outcomes
The primary efﬁcacy analysis was restricted to patients with
prior TNF antagonist failure (ie, TNF antagonist–failure popu-
lation, prespeciﬁed as w75% of enrolled patients), among
whom the proportion of patients in clinical remission at week 6
was assessed (Figure 2). Secondary efﬁcacy outcomes were the
proportion of patients in the overall study population (including
an additional w25% of TNF antagonist–naive patients) in
remission at week 6, proportions of patients in the overall and
TNF antagonist–failure populations in remission at week 10,
proportions of patients in the overall and TNF antagonist–
failure populations with remission at both weeks 6 and
week 10, and the proportion of patients in the TNF antagonist–
failure population with a CDAI-100 response at week 6.
Prespeciﬁed exploratory outcomes included the proportion
of patients in the overall population who had a CDAI-100
response at week 6 and proportions of patients in the overall
and TNF antagonist–failure populations who had a CDAI-100response at week 10, as well as changes from baseline to
weeks 6 and 10 in CRP concentration (among patients with
increased baseline CRP concentration [>2.87 mg/L]) and from
baseline to week 6 in fecal calprotectin level. To summarize
efﬁcacy in important subgroups and further clarify primary
and secondary outcomes, additional prespeciﬁed exploratory
analyses were performed, including clinical remission and
CDAI-100 response at weeks 6 and 10 and remission at both
weeks 6 and 10 in patients who were naive to TNF antagonist
therapy and remission at weeks 6 and 10 and CDAI-100
response at week 6 in subgroups deﬁned by concomitant
corticosteroid or immunosuppressive use.
Safety Outcomes
Adverse events, serious adverse events (SAEs), standard
clinical laboratory test results, and vital signs were evaluated.
Monitoring for PML
Consistent with all vedolizumab clinical studies conducted
since 2006, the development of new neurologic signs and symp-
toms potentially consistent with PML was monitored in a risk
minimization program27 featuring standardized questionnaires
and a stepwise diagnostic algorithm overseen by an independent
committee of PML experts. The committee adjudicated potential
cases and provided further guidance for the investigator and
study sponsor in situations of clinical uncertainty.
Pharmacokinetics and Immunogenicity
Blood samples for pharmacokinetic evaluation were
collected postdose at week 0, predose and postdose at week 6,
and at any time during the study visit at week 10 and any
unscheduled disease exacerbation -related visit. Blood samples
for anti–vedolizumab antibody assessment were collected
predose at weeks 0, 6, 10, and 22, and during any unscheduled
disease exacerbation–related visit.
Statistical Analyses
All efﬁcacy analyses were performed for patients from
intention-to-treat populations who had received any amount of
blinded study drug; missing efﬁcacy data were considered
therapy failure. The safety population was deﬁned as all pa-
tients who received any amount of study drug. Populations for
pharmacokinetic analyses were deﬁned as all patients who
received 1 or more doses of study drug and underwent sufﬁ-
cient blood sampling for pharmacokinetic evaluation.
All proportion-based outcomes (Supplementary Figure 1)
were analyzed using the Cochran–Mantel–Haenszel chi-square
test at a statistical signiﬁcance level of 0.05 with stratiﬁcation
according to previous TNF antagonist status, concomitant corti-
costeroid use, and concomitant immunosuppressive use. The
Cochran–Mantel–Haenszel chi-square P value, risk difference
(primary test), and associated 2-tailed 95% conﬁdence intervals
(CIs) were determined, as were the relative risk and its 2-tailed
95% CI. Secondary analyses were performed sequentially, with a
P value of .05 or less required to proceed to testing of each
subsequent outcome. Of the 6 secondary analyses, 4 (ie, 2 pairs
of outcomes, each pair evaluating 1 end point for the 2 pop-
ulations) involved simultaneous testing for the TNF antago-
nist–failure and overall populations (Supplementary Figure 1).
Table 1.Demographics and Baseline Characteristics
Characteristic
Placebo Vedolizumab
Overall population
(n ¼ 207)
TNF antagonist–failure
population (n ¼ 157)
TNF antagonist–naive
subgroup (n ¼ 50)
Overall population
(n ¼ 209)
TNF antagonist–failure
population (n ¼ 158)
TNF antagonist–naive
subgroup (n ¼ 51)
Women, n (%) 118 (57) 95 (61) 23 (46) 118 (56) 90 (57) 28 (55)
Median age, y (range) 34.8 (19–77) 36.6 (19–77) 30.6 (19–60) 36.9 (20–69) 37.5 (20–69) 35.7 (20–64)
Mean body weight, kg (range) 71.3 (41–147) 71.2 (41–125) 71.7 (43–147) 69.5 (40–144) 70.3 (40–144) 67.1 (40–99)
Median body mass index, kg/m2
(range)
23.3 (15–48) 23.3 (15–48) 22.9 (17–43) 23.3 (15–43) 23.3 (15–43) 22.6 (16–33)
Median Crohn’s disease duration,
y (range)
8.0 (0.3–42.9) 9.6 (1.0–42.9) 4.4 (0.3–24.8) 8.4 (0.3–41.8) 9.4 (0.5–41.8) 4.7 (0.3–40.8)
Mean CDAI score (SD) 301.3 (55.0) 306.1 (55.4) 286.1 (51.1) 313.9 (53.2) 316.1 (52.6) 307.3 (54.8)
Mean CRP level, mg/L (SD) 18.5 (22.0) 18.8 (23.6) 17.7 (16.1) 19.0 (23.2) 20.7 (24.7) 13.9 (16.8)
Mean fecal calprotectin level,
mg/g stool (SD)
1426.5 (2357.8) 1459.5 (2475.0) 1321.0 (1954.0) 1148.1 (1878.6) 1249.2 (2071.6) 836.9 (1043.8)
Disease localization, n (%)
Ileum only 29 (14) 20 (13) 9 (18) 33 (16) 21 (13) 12 (24)
Colon only 52 (25) 40 (25) 12 (24) 48 (23) 40 (25) 8 (16)
Ileocolonic (both ileum and
colon)
126 (61) 97 (62) 29 (58) 128 (61) 97 (61) 31 (61)
History of Crohn’s disease
surgery, n (%)
89 (43) 80 (51) 9 (18) 92 (44) 73 (46) 19 (37)
History of ﬁstulizing disease, n (%) 77 (37) 67 (43) 10 (20) 71 (34) 57 (36) 14 (27)
Corticosteroid use, n (%) 108 (52) 85 (54) 23 (46) 110 (53) 86 (54) 24 (47)
Immunosuppressive use, n (%) 69 (33) 42 (27) 27 (54) 71 (34) 43 (27) 28 (55)
Mesalamine use, n (%)a 61 (29) 29 (18) 32 (64) 68 (33) 37 (23) 31 (61)
Prior immunosuppressive
exposure, n (%)
193 (93) 147 (94) 46 (92) 176 (84) 135 (85) 41 (80)
Prior TNF antagonist failure,
n (%)b
157 (76) 157 (100) - 158 (76) 158 (100) -
1 prior TNF antagonist
failure, n (%)b
45 (22)c 43 (27)c - 59 (28)c 59 (37)c -
2 prior TNF antagonist
failures, n (%)b
90 (43)c 90 (57)c - 82 (39)c 82 (52)c -
3 prior TNF antagonist
failures, n (%)b
21 (10)c 21 (13)c - 14 (7)c 14 (9)c -
NOTE. Missing/unreported values in the TNF antagonist–failure population: placebo, n ¼ 3; vedolizumab, n ¼ 3. Missing/unreported values in the overall population:
placebo, n ¼ 51; vedolizumab, n ¼ 54.
aUsed by patients at any time during the study.
bMultiple failures are counted once per patient.
cData on numbers of patients with 1, 2, and 3 TNF antagonist failures were captured via electronic case report form only (not via interactive voice response system).
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Figure 2. Patient disposi-
tion. aAll 416 patients
received at least 1 dose of
blinded study drug and
comprised the overall
population for efﬁcacy an-
alyses as well as the safety
population. bOf the 416
randomly assigned pa-
tients, 25%, 41%, and 8%
had 1, 2, and 3 TNF antag-
onist failures, respectively.
These data were captured
via electronic case report
form only (not via inter-
active voice response
system). ITT, intention-to-
treat.
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pair to maintain the overall type 1 error rate at a P value of .05
or less. A logistic regression model, including baseline CDAI
score, stratiﬁcation factors, and geographic region, was con-
ducted as a sensitivity analysis using the chi-square test at a
statistical signiﬁcance level of 0.05; the chi-square P value and
odds ratio, with associated 95% CIs, were determined. Analysis
of covariance models of change from baseline to week t for the
continuous efﬁcacy outcome variables in the vedolizumab and
placebo groups was performed. For the prespeciﬁed exploratory
analyses of TNF antagonist–naive patients and for those based
on concomitant corticosteroid or immunosuppressive use, P
values were determined and 95% CIs were calculated using the
exact method (for categoric data with numerators 5) or the
normal approximation.
Power estimates for the primary and secondary outcomes
were 91% and 81%–93%, respectively, on the basis of total
sample sizes of 296 for the TNF antagonist–failure population
and 396 for the overall population.Results
Patients
A total of 660 patients were screened (Figure 2), of whom
244 were excluded because of not meeting enrollment
criteria (n¼ 209), withdrawal of consent (n¼ 11), having an
SAE (n ¼ 5), having a protocol violation (n ¼ 1), or other/
unknown reasons (n¼ 18). Of 416 randomized patients, 315
(76%) had previous failure of (ie, inadequate response to,
loss of response to, or intolerance of) 1 or more TNF antag-
onists, and 101 patients (24%) were TNF-antagonist naive.
Demographic characteristics (Table 1) generally were
similar between treatment groups in the TNF antago-
nist–failure population. Corticosteroids were the mostcommon concomitant medications used at any time during
the study (54% of patients), followed by immunosuppres-
sives (34%) and mesalamine (31%). Previous immunosup-
pressive exposure was reported by 89% of patients. In the
TNF antagonist–failure population, 2 or more TNF antago-
nists had failed in 66% of patients (44% of whom had a
primary nonresponse), whereas 3 TNF antagonists had
failed in 11% of patients.Efﬁcacy
For the primary outcome, the proportion of patients in
clinical remission at week 6 for the TNF antagonist–failure
population (Figure 3A), no statistically signiﬁcant difference
was observed between the vedolizumab (15.2%) and pla-
cebo (12.1%) groups (P ¼ .433; relative risk, 1.2; 95% CI,
0.7–2.2). Because this outcome was not statistically signiﬁ-
cant, formal hypothesis testing of ranked secondary out-
comes was not performed. Nominal P values, relative risks,
and 95% CIs are presented for descriptive purposes to fully
characterize the effect of vedolizumab induction treatment
in this population.
Secondary and prespeciﬁed exploratory out-
comes: TNF antagonist–failure population. In the TNF
antagonist–failure population, greater proportions of
vedolizumab-treated patients than placebo-treated patients
were in clinical remission at week 10 (Figure 3B; vedoli-
zumab, 26.6%; placebo, 12.1%; P ¼ .001; relative risk, 2.2;
95% CI, 1.3–3.6). The between-group difference in rates of
remission both weeks 6 and 10 (Figure 3C) was not less
than 0.05 in this population (vedolizumab, 12.0%; placebo,
8.3%; P ¼ .276; relative risk, 1.4; 95% CI, 0.7–2.8). Greater
proportions of vedolizumab-treated patients also had a
CDAI-100 response at week 6 (Figure 3D; vedolizumab,
Figure 3. Treatment efﬁcacy: clinical remission (CDAI score, 150 points) at (A) week 6, at (B) week 10, and at (C) both weeks 6
and 10; CDAI-100 response (100-point reduction from baseline in CDAI score) at (D) week 6 and at (E) week 10 for the TNF
antagonist–failure and overall populations and the TNF antagonist–naive subgroup. aPrimary outcome. bNominal P values and
95% CIs are presented for descriptive purposes to fully characterize the effect of vedolizumab induction treatment in these
populations. D, difference from placebo.
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1.2–2.5) and at week 10 (Figure 3E; vedolizumab, 46.8%;
placebo, 24.8%; P < .0001; relative risk, 1.9; 95% CI,
1.4–2.6).
Secondary and prespeciﬁed exploratory out-
comes: overall population. In the overall population, a
greater proportion of vedolizumab-treated patients (19.1%)
than placebo-treated patients (12.1%) was in clinical
remission at week 6 (Figure 3A; P ¼ .048; relative risk, 1.6;
95% CI, 1.0–2.5). As in the TNF antagonist–failure popula-
tion, a greater proportion of the overall population was in
remission at week 10 with vedolizumab than with placebo
(Figure 3B; vedolizumab, 28.7%; placebo, 13.0%; P < .0001;
relative risk, 2.2; 95% CI, 1.4–3.3). The nominal P value for
the between-group difference in rates of remission at both
weeks 6 and 10 was less than .05 in the overall population
(Figure 3C; vedolizumab, 15.3%; placebo, 8.2%; P ¼ .025;
relative risk, 1.9; 95% CI, 1.1–3.2). Prespeciﬁed exploratory
analyses in the overall population showed that the propor-
tion of patients with a CDAI-100 response was greater with
vedolizumab at week 6 (Figure 3D; vedolizumab, 39.2%;
placebo, 22.7%; P ¼ .0002; relative risk, 1.7; 95% CI,
1.3–2.3) and at week 10 (Figure 3E; vedolizumab, 47.8%;
placebo, 24.2%; P < .0001; relative risk, 2.0; 95% CI,
1.5–2.6).
Prespeciﬁedexploratoryoutcomes:TNFantagonist–
naive subgroup and effects of concomitant CD
therapy. Although the TNF antagonist–naive subgroup
(Figure 3) was relatively small, proportions of patients were
greater with vedolizumab than with placebo for the following
outcomes: clinical remission at week 6 (vedolizumab, 31.4%;
placebo, 12.0%; P ¼ .012; relative risk, 2.6; 95% CI, 1.1–6.2);
remission at week 10 (vedolizumab, 35.3%; placebo, 16.0%;
P ¼ .025; relative risk, 2.2; 95% CI, 1.1–4.6); remission at
both weeks 6 and 10 (vedolizumab, 25.5%; placebo, 8.0%;P ¼ .018; relative risk, 3.2; 95% CI, 1.1–9.1); CDAI-100
response at week 6 (vedolizumab, 39.2%; placebo, 24.0%;
P ¼ .088; relative risk, 1.6; 95% CI, 0.9–2.9); and CDAI-100
response at week 10 (vedolizumab, 51.0%; placebo, 22.0%;
P ¼ .002; relative risk, 2.3; 95% CI, 1.3–4.2).
Prespeciﬁed exploratory subgroup analysis results by
concomitant corticosteroid or immunosuppressive use for
clinical remission at weeks 6 and 10 and CDAI-100 response
at week 6 for the TNF antagonist–failure and overall pop-
ulations are shown in Supplementary Figures 2 and 3.Prespeciﬁed Exploratory Biomarker Outcomes:
C-Reactive Protein and Fecal Calprotectin
Concentrations
Among patients in the TNF antagonist–failure and overall
populations with increased baseline CRP levels, median
changes in CRP concentration were improved modestly from
baseline to weeks 6 and 10; these improvements were more
pronounced at week 10 than at week 6 (Supplementary
Figure 4). Nominal P values for between-group differences
in median change in fecal calprotectin levels from baseline to
week 6 were not less than .05 among the TNF antago-
nist–failure population (vedolizumab, -22.1 mg/g stool; pla-
cebo, -5.0 mg/g stool; P ¼ .883) or the overall population
(vedolizumab, -26.2 mg/g stool; placebo, -7.8 mg/g stool;
P ¼ .744).Safety
Sixty percent of placebo-treated patients and 56% of
vedolizumab-treated patients experienced 1 or more AEs
during the study (Table 2). Serious infection and drug-
related SAEs were experienced by 1% or less of patients
in both groups, and 2% of patients in both groups had SAEs
Table 2.Treatment-Emergent Adverse Events in the Overall
Safety Population
Event
Overall safety population
(patients who received
any amount of study drug)
(N ¼ 416), No. (%)
Placebo
(n ¼ 207)
Vedolizumab
(n ¼ 209)
Any adverse event 124 (60) 117 (56)
Drug-related adverse event 34 (16) 34 (16)
Discontinued because of
adverse events
8 (4) 4 (2)
Serious adverse events 16 (8) 13 (6)
Serious infection 0 2 (<1)
Drug-related serious
adverse event
1 (<1) 1 (<1)
Discontinued because of
serious adverse events
5 (2) 4 (2)
Adverse event in >1% of
vedolizumab patients,
categorized by preferred
term
Nausea 5 (2) 12 (6)
Headache 15 (7) 11 (5)
Upper respiratory tract infection 5 (2) 9 (4)
Arthralgia 9 (4) 10 (5)
Nasopharyngitis 8 (4) 9 (4)
Abdominal pain 6 (3) 9 (4)
Crohn’s disease exacerbation 21 (10) 6 (3)
Pyrexia 13 (6) 7 (3)
Aphthous stomatitis 3 (1) 4 (2)
Vomiting 5 (2) 9 (4)
Fatigue 2 (<1) 6 (3)
Urinary tract infection 0 6 (3)
Dizziness 4 (2) 5 (2)
Anemia 1 (<1) 5 (2)
Musculoskeletal pain 0 4 (2)
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ATleading to study discontinuation. No deaths were reported
in the study.
The most common AEs in both groups were similar and
included infections (vedolizumab, 19%; placebo, 17%).
Gastrointestinal infections occurred in 5 (2%) vedolizumab-
treated patients and in 3 (1%) placebo-treated patients. In
vedolizumab-treated patients, the most common AEs were
nausea, vomiting, headache, upper respiratory tract infec-
tion, arthralgia, nasopharyngitis, and abdominal pain
(Table 2). Incidences of nausea, upper respiratory tract
infection, arthralgia, abdominal pain, aphthous stomatitis,
vomiting, fatigue, urinary tract infection, and anemia were
higher with vedolizumab, whereas incidences of CD exac-
erbation, pyrexia, and headache were higher with placebo.
Two vedolizumab-treated patients had SAEs of infection,
including 1 anal abscess and 1 urinary tract infection, which
were treated successfully during the study; neither led to
study discontinuation. No placebo-treated patients had
SAEs of infection. Infusion-related AEs occurred in 4
(2%) vedolizumab-treated patients and in 2 (<1%) placebo-
treated patients. In the 1 patient who reported newneurologic symptoms during the study and was evaluated
by an independent adjudication committee, PML formally
was excluded. This vedolizumab-treated patient was later
withdrawn from the study because of an ependymoma and
had the only reported neoplasm in the study.
Pharmacokinetics and Immunogenicity
The mean  SD week 6 trough vedolizumab serum
concentration was 26.5  15.8 mg/mL (n ¼ 195), which was
similar to that observed in GEMINI 2.24 The week 10
vedolizumab serum concentration was 28.4  17.9 mg/mL
(n ¼ 190). Of 209 vedolizumab-treated patients, 3 (1%) had
positive test results for antivedolizumab antibodies at any
time point; 1 of these 3 patients had neutralizing antibodies,
and none had persistently positive (ie, positive status at 2
consecutive visits) antibody status. The limited number
of patients in whom antibodies were observed and the
short study duration precluded meaningful analysis of po-
tential correlations of pharmacokinetics and efﬁcacy with
immunogenicity.
Discussion
Efﬁcacy and safety of vedolizumab induction therapy
were evaluated in this randomized, blinded, placebo-
controlled study of patients with moderately to severely
active CD. In the TNF antagonist–failure population (w75%
of patients), there were high rates of long-standing disease,
prior CD surgery, history of ﬁstulizing disease, baseline CRP
and fecal calprotectin increases, and prior failure of immu-
nosuppressives and multiple TNF antagonists.
In the TNF antagonist–failure population, vedolizumab
was not statistically superior to placebo for inducing clinical
remission at week 6. However, secondary and exploratory
outcome results suggest that vedolizumab had clinically
relevant activity in TNF antagonist–failure and TNF antag-
onist–naive patients.
Collectively, the primary and secondary outcome results
suggest that in patients with CD and previous TNF antago-
nist failure, effects of vedolizumab on clinical remission may
not become evident until between weeks 6 and 10. Week 10
secondary outcomes were prespeciﬁed to test the hypoth-
esis that the time to achieve remission with vedolizumab
may be 10 weeks in patients with CD, particularly in
patients with previous TNF antagonist failure. Results in
the TNF antagonist–failure population showed a clinically
important increase over time in the proportion of
vedolizumab-treated patients in remission, from 15.2% at
week 6 to 26.6% at week 10. However, the remission rate in
placebo-treated patients remained constant at 12.1% at
weeks 6 and 10.
Similar analyses of the overall population showed more
vedolizumab-treated patients (19.1%) than placebo-treated
patients (12.1%) in clinical remission at week 6 (treatment
difference, 7.0%; 95% CI, 0.1%–13.8%; P ¼ .048). This dif-
ference resulted fromthemore robust effect on this outcome in
the smaller TNF antagonist–naive subgroup, which comprised
24% of the overall population. On the basis of observed dif-
ferences among the TNF antagonist–naive subgroups in
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have a more pronounced effect before the onset of structural
damage, as indirectly gauged by shorter disease duration and
lack of prior CD surgery. These disease characteristics were
considerably more common in TNF antagonist–naive patients
than in patients with prior TNF antagonist failure. Similar
trends toward more pronounced effects of treatment in TNF
antagonist–naive patients also have been seenwith the use of a
second or third TNF antagonist and with natalizumab. An in-
crease in remission rates fromweek 6 to 10 alsowas observed
among vedolizumab-treated patients in the overall population.
Collectively, these ﬁndings indicate that additional beneﬁts of
vedolizumab treatment may accrue between weeks 6 and 10,
regardless of previous TNF antagonist response, and could be
associated with effects of an additional vedolizumab dose at
week 6 or with the incremental effect of time on the drug’s
ability to exert a therapeutic beneﬁt. Similarﬁndingshavebeen
observedwithnatalizumab induction therapy,6which suggests
that a gradual onset of efﬁcacymaybeanattributeofdrugs that
modulate lymphocyte trafﬁcking. This observation may help
with the optimization of vedolizumab induction therapy in
real-world settings.
The lack of statistical signiﬁcance of primary outcome
results contrasts with the GEMINI 2 induction study results
in patients with previous TNF antagonist failure.24 However,
several patient characteristics and design parameters
differed between these 2 studies (eg, differences in upper
CDAI score cut-off values, deﬁned by entry criteria, and in
mean CDAI scores, and re-randomization at week 6 in
GEMINI 2). In a prespeciﬁed subgroup analysis of patients
from GEMINI 2 with previous TNF antagonist failure, the
proportion of patients with week 6 clinical remission was
similar between vedolizumab-treated (10.5%) and placebo-
treated groups (4.3%; treatment difference, 6.2%; 95% CI,
-9.1% to 21.3%). In a prespeciﬁed subgroup analysis of TNF
antagonist–naive patients from GEMINI 2, the week 6
remission rate was higher with vedolizumab (17.4%) than
with placebo (9.2%; treatment difference, 8.2%; 95% CI,
-1.4% to 17.9%). The week 6 treatment difference in patients
with previous TNF antagonist failure was similar in GEMINI 3
(3.0%) and GEMINI 2 (6.2%), whereas the week 6 treatment
difference in TNF antagonist–naive patients was larger in
GEMINI 3 (19.2%) than in GEMINI 2 (8.2%). Observed dif-
ferences in week 6 remission rates between overall pop-
ulations of the 2 studies may be attributable to variations
between 2 otherwise similar patient populations, including
proportions of patients with previous exposure to 1, 2, or 3
TNF antagonists (GEMINI 2, 47.6%; GEMINI 3, 75.7%). The
upper bound of patients’ CDAI scores (GEMINI 2, 450;
GEMINI 3, 400) or random variation could have accounted
for the observed differences in subgroup analyses of week 6
remission rates among TNF antagonist–naive patients.
Effects of vedolizumab induction therapy were modest
overall, and maintenance effects were not evaluated in this
short-term study; however, the modest efﬁcacy of vedoli-
zumab induction therapy in GEMINI 2 was contrasted by the
pronounced beneﬁt of vedolizumab maintenance therapy
over the course of 52 weeks. Among vedolizumab induction
responders in GEMINI 2, week 52 clinical remissionoccurred in 39.0% (P < .001) and 36.4% (P ¼ .004) of
patients who continued vedolizumab every 8 and 4 weeks,
respectively, and in 21.6% of patients who were assigned
randomly to switch to placebo during maintenance. Effects
were similar for week 52 CDAI-100 response and
corticosteroid-free remission rates. In GEMINI 2, the main-
tenance beneﬁt of vedolizumab was consistent between
patients with previous TNF antagonist failure and in TNF
antagonist–naive patients.
Observed effects of vedolizumab on disease activity
biomarkers were small, but evident, and were consistent
with the efﬁcacy data. Effects on CRP concentration in
patients with increased CRP levels at baseline were less
pronounced than effects seen after TNF antagonist treat-
ment in other studies.28–30 The apparently slower CRP
reduction kinetics warrant careful consideration. Previ-
ously, TNF was reported to exert a direct effect on CRP
production by the liver.31 Because vedolizumab, unlike TNF
antagonists, does not antagonize TNF directly and may not
affect the mesentery, an important source of CRP in CD,32 it
is scientiﬁcally plausible to speculate that the reduction in
mucosal inﬂammation resulting from inhibition of leuko-
cyte trafﬁcking causes an indirect (ie, secondary) CRP
concentration reduction that occurs gradually, as seen over
the course of 52 weeks in GEMINI 2.24 In contrast, TNF
antagonism may result in direct and indirect effects on
CRP. Week 6 assessments of fecal calprotectin, a biomarker
that has been studied less extensively in CD than in ul-
cerative colitis (UC), did not show a clinically meaningful
difference between treatment groups; however, because
these assessments were not conducted at week 10, it is
unclear if an effect of vedolizumab would have become
more apparent over time. Future studies are warranted to
evaluate the potential healing effects of vedolizumab on the
ileocolonic mucosa in patients with CD and to establish an
optimal methodology for analysis of drug effects on fecal
calprotectin levels in CD.
Results of this short-term study support the safety of
vedolizumab in patients with CD and are consistent with the
drug’s postulated gut-selective mechanism of action. The
safety proﬁle in GEMINI 3 generally is consistent with that
in the pivotal trials GEMINI 1 (UC) and 2 (CD), in which no
statistically signiﬁcant differences in treatment-emergent
SAE incidences occurred between the vedolizumab and
placebo groups.24,33,34 Although upper respiratory tract
infection rates were similar between treatment groups in
this study, across previous clinical studies, vedolizumab was
associated with an increased risk of such infections.24,33,34
This association is potentially consistent with its mecha-
nism of action, namely antagonism of a4b7/MAdCAM-1
interactions in upper respiratory/aerodigestive tract tis-
sues.35 Upper respiratory tract infections with vedolizumab
generally have been mild or moderate in severity, requiring
no interventions, and an increased risk of lower respiratory
tract infections (eg, bronchitis and pneumonia) has not been
observed. As previously noted, natalizumab, the only avail-
able biologic therapy with a mechanism that differs from
that of TNF antagonists,36 rarely is used in CD because of the
risk of PML.17,18 Consistent with the expected lack of effect
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blockade of lymphocyte trafﬁcking with vedolizumab,20,22
no PML cases have been identiﬁed in the vedolizumab
development program to date. As of June 27, 2013, there
were 3129 patients with CD or UC who had received
vedolizumab in 11 clinical studies (including GEMINI 1, 2, 3,
and the GEMINI long-term extension study) for a median of
313 days (mean, 481 days; range, 1–1977 days). Accounting
for a pharmacologic effect duration of approximately 16
weeks after the last vedolizumab dose, 995 of these patients
had been exposed to vedolizumab for at least 24 months. If
the incidence of PML in patients receiving vedolizumab was
similar to that in patients with multiple sclerosis receiving
natalizumab (ie, >1 case in 500 patients) before the appli-
cation of known risk-stratiﬁcation factors (ie, therapy
duration, previous immunosuppressive use, and JC virus
seropositivity),17 it is estimated that 6 to 7 cases would have
been seen among vedolizumab-exposed patients. Although
no PML cases have been reported in the integrated vedoli-
zumab safety database, additional longer-term observa-
tional data are needed to exclude any potential of
developing PML as a result of vedolizumab exposure.
In conclusion, vedolizumab was not statistically superior
to placebo in achieving clinical remission at week 6 among
patients with moderately to severely active CD and previous
TNF antagonist failure. Several prespeciﬁed outcomes sug-
gest that vedolizumab may lead to clinical remission in TNF
antagonist–naive patients with CD and at 10 weeks in TNF
antagonist–failure patients. These clinically relevant re-
sponse kinetics have potential implications for bridging in-
duction therapy to vedolizumab maintenance therapy,
which has established efﬁcacy, in patients with this lifelong
condition. The safety proﬁle of vedolizumab was generally
similar to that of placebo in this short-term study and was
consistent with that of longer-term vedolizumab use in
previous studies.
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Supplementary
Figure 1. Efﬁcacy out-
comes and testing order.
CDAI, Crohn’s Disease
Activity Index; TNF, tumor
necrosis factor.
Supplementary Figure 2. Clinical remission and CDAI-100 response by corticosteroid (CS) use: proportions of patients in
clinical remission (CDAI score, 150 points) by CS use at (A) week 6 and (B) week 10 for the TNF antagonist–failure population
and overall population; proportions of patients with a CDAI-100 response (100-point reduction from baseline in CDAI score) by
CS use at (C) week 6 for the TNF antagonist–failure population and overall population. PBO, placebo; VDZ, vedolizumab.
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Supplementary Figure 3. Clinical remission and CDAI-100 response by immunosuppressive (IS) use: proportions of patients
in clinical remission (CDAI score, 150 points) by IS use at (A) week 6 and (B) week 10 for the TNF antagonist–failure pop-
ulation and overall population; proportions of patients with a CDAI-100 response (100-point reduction from baseline in CDAI
score) by IS use at (C) week 6 for the TNF antagonist–failure population and overall population. PBO, placebo; VDZ,
vedolizumab.
Supplementary Figure 4.Median changes in CRP concentration at (A) week 6 and (B) week 10 among patients with abnormal
CRP concentrations (>2.87 mg/L) at baseline in the TNF antagonist–failure population and the overall population. CRP,
C-reactive protein.
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Supplementary Table 1.Deﬁnitions of Inadequate Response, Intolerance, and Loss of Response Over the Previous
5-Year Perioda
Inadequate response to corticosteroids
Signs and symptoms of persistently active disease despite a history of at least one 4-week induction regimen that included a dose
equivalent to prednisone 30 mg/day, orally for 2 weeks or intravenously for 1 week
OR
Two failed attempts to taper corticosteroids to below a dose equivalent to prednisone 10 mg/day, orally on 2 separate occasions
Intolerance to corticosteroids
History of intolerance to corticosteroids (including, but not limited to, Cushing’s syndrome, osteopenia/osteoporosis, hyperglycemia,
insomnia, and infection)
Inadequate response to immunosuppressives
Signs and symptoms of persistently active disease despite a history of at least one 8-week regimen of azathioprine (1.5 mg/kg),
6-mercaptopurine (0.75 mg/kg), or methotrexate (12.5 mg/wk)
Intolerance to immunosuppressives
History of intolerance to 1 immunosuppressive (including, but not limited to, nausea/vomiting, abdominal pain, pancreatitis, liver function
test abnormalities, lymphopenia, thiopurine methyltransferase genetic mutation, and infection)
Inadequate response to TNF antagonists
Signs and symptoms of persistently active disease despite a history of at least one 4-week induction regimen of 1 of the following agents
Inﬂiximab: 5 mg/kg intravenously, 2 doses at least 2 weeks apart
Adalimumab: one 80-mg subcutaneous dose followed by one 40-mg dose 2 weeks apart
Certolizumab pegol: 400 mg subcutaneously, 2 doses 2 weeks apart
Intolerance to TNF antagonists
History of intolerance to at least 1 TNF antagonist (including, but not limited to, infusion-related reaction, demyelination, congestive heart
failure, and infection)
Loss of response
Recurrence of symptoms during scheduled maintenance dosing after prior clinical beneﬁt (discontinuation despite clinical beneﬁt does not
qualify)
aPatients who enrolled in the study had an inadequate response, did not respond or were intolerant to 1 corticosteroid,
immunosuppressive, or TNF antagonist; US patients must have failed either immunosuppressive or TNF antagonist therapy (ie,
not corticosteroids only).
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